focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 63.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.175%)
Open: 64.00
High: 64.00
Low: 64.00
Prev. Close: 64.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 - NetScientific PLC

27 Nov 2018 10:33

RNS Number : 6220I
W.H. Ireland Limited
27 November 2018
 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

WH Ireland Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

NetScientific PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

NetScientific PLC

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

26/11/2018

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

NetScientific PLC 5p Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

3,573

0.00

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

3,573

0.00

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary 5p

 

Ordinary 5p

Purchases

 

Sales

 

50,000

 

100,000

26p

 

27p

26p

 

27p

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

27/11/2018

Contact name:

Christopher Houghton

Telephone number:

0161 819 8866

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEOPGGPWGUPRGUM
Date   Source Headline
3rd Apr 20184:09 pmRNSPosting of Circular
29th Mar 20187:00 amRNSProposed Placing and Subscription
29th Mar 20187:00 amRNSFull Year Results
19th Mar 20187:00 amRNSWanda Expanding to Orthopedic Analytics
13th Mar 20187:00 amRNSVortex Announces Partnership with BioView
15th Feb 20187:00 amRNSProAxsis Reports First NEATstik Sale
9th Feb 20187:00 amRNSVortex Releases Publication in Nature Scientific
16th Jan 20187:00 amRNSNetScientific Portfolio Update
8th Jan 20187:00 amRNSProAxsis Achieves CE Mark for Plasmin Immunoassay
4th Jan 20187:00 amRNSGlycotestT Completes Diagnostic Evaluation
12th Dec 20177:00 amRNSWanda Awarded Two Patents
21st Nov 20177:00 amRNSProAxsis: Sales Update
7th Nov 20177:00 amRNSVortex Announces First Commercial VTX-1 Sale
2nd Nov 20177:00 amRNSGlycotest Adds Allowed Chinese Patent to Portfolio
1st Nov 201711:00 amRNSVortex Announces Liquid Biopsy Study in NPJ
30th Oct 20177:00 amRNSProAxsis Showcases ProteaseTag® Research at NACFC
27th Oct 20177:00 amRNSProAxsis Partnership - US National Jewish Health
25th Oct 20177:00 amRNSDirectorate Change
5th Oct 20177:00 amRNSGlycotest Granted Japanese Patent
2nd Oct 20177:00 amRNSWanda Awarded US Patent
28th Sep 20177:00 amRNS2017 Interim Results
14th Sep 20177:00 amRNSProAxsis appoints Diagenics Limited as Distributor
11th Sep 20177:00 amRNSProAxsis Signs Partnership: Biotechnology Company
7th Sep 20177:00 amRNSNotice of Interim Results
4th Sep 20177:00 amRNSProAxsis is awarded a European CE Mark
24th Jul 20177:00 amRNSProAxsis awarded a Significant Innovate UK Grant
10th Jul 201712:00 pmRNSPDS Announces Clinical Collaboration with Merck
7th Jul 20177:00 amRNSGlycotest Strengthens Intellectual Property Reach
26th Jun 20177:00 amRNSGlycotest Update
21st Jun 201712:00 pmRNSResult of AGM
16th Jun 201710:05 amRNSHoldings in Company
15th Jun 20172:52 pmRNSHoldings in Company
12th Jun 201712:02 pmRNSResults of General Meeting
12th Jun 201711:10 amRNSResult of Placing
26th May 20173:52 pmRNSNotice of AGM and Annual Report & Accounts
26th May 201712:49 pmRNSResults of Placing and Subscription
25th May 201711:51 amRNSProposed Placing and Subscription
24th May 20177:00 amRNSVortex Initiates Clinical Research Studies
10th May 20177:00 amRNSProAxsis announces additional IP
5th May 20177:00 amRNSProAxsis Presents New Data at Major US Conference
24th Apr 20177:00 amRNSBTG purchases Wanda's shares in Oncoverse
3rd Apr 20177:00 amRNSFull Year Results for the year ended 31 Dec 2016
31st Mar 20177:00 amRNSVortex Biosciences Announces Publications
27th Mar 20177:00 amRNSNotice of Preliminary Results
22nd Feb 20177:00 amRNSVortex Biosciences Launches VTX-1 Liquid Biopsy
15th Feb 20177:00 amRNSVortex Biosciences' CSO Wins SLAS Innovation Award
9th Feb 20177:00 amRNSVortex Biosciences' CSO Finalist for SLAS Award
30th Jan 20177:00 amRNSGrant of Options to Directors
20th Dec 20167:00 amRNSNew CEO appointed to Wanda
16th Dec 20167:00 amRNSExecuted Warrants

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.